logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
C

Christopher Pieczonka

University of Helsinki

16H-index
185Paper Count
1.8KCitation Count
Published Papers 44
Publication Date
logo
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial
errJournal of Urology
IF6.8
err2026-05-01
err6
PREAI
errShore, Neal D.; Gleave, Martin; De Giorgi, Ugo; Rannikko, Antti; Pieczonka, Christopher M.; Sridharan, Swetha; Brasso, Klaus; Woo, Henry H.; Gomez Caamano, Antonio; Saranchuk, Jeff W.; Nordquist, Luke T.; Ferreira, Ubirajara; Tang, Yiyun; Rosbrook, Brad; Haas, Gabriel P.; Rosales, Matt; Zohren, Fabian; Tarazi, Jamal; Freedland, Stephen J.
errShare
errSave
Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels
errCurrent Opinion in Urology
IF2.2
err2026-01-01
err0
PREAI
errPradere, Benjamin; Schuit, Maarten; Guerrero-Ramos, Felix; Shariat, Shahrokh F.; Kitamura, Hiroshi; Jacob, Joseph M.; Bao, Yige; Heesakkers, John; Peters, Kenneth M.; Cahn, David J.; De Troyer, Bart; Herrera Imbroda, Bernardo; Morris, David S.; Pieczonka, Christopher M.; Wei, Qiang; Bhanvadia, Sumeet; Somer, Robert; Jessner, Wolfgang; Triantos, Spyros; Sanchez de Llano, Cristina; Maffeo, John C.; Sweiti, Hussein; Psutka, Sarah P.
errShare
errSave
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis
errProstate Cancer and Prostatic Diseases
IF5.8
err2025-11-01
err0
errOAAI
errEvan Y. Yu; Hiroyoshi Suzuki; Christopher M. Pieczonka; Geoffrey Gotto; Alberto Briganti; Murilo Luz; Declan Murphy; Ryan Malone; Joelle Hamilton; Jonathan E. Chan; Paul Sieber; Robert W. Given; Eva Hellmis; Thomas Kretz; Philipp Spiegelhalder; Antonio Gómez-Caamaño; Yaovi Messan Amela; Xavier Artignan; Hiroji Uemura; Naoki Fujita; Patrick Adorjan; Mercedeh Ghadessi; Frank Verholen; Andrew J. Armstrong
errShare
errSave
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
errThe Lancet Oncology
IF0
err2025-10-27
err0
PREAI
errMatthew Smith; Josep Piulats; Tilman Todenhöfer; Jae-Lyun Lee; José Arranz Arija; Laura Mazilu; Arun Azad; Teresa Alonso-Gordoa; Ursula McGovern; Atish Choudhury; Lisa Horvath; Dingwei Ye; Weiqing Han; Hiroyoshi Suzuki; Hiroji Uemura; Rana McKay; Steven Ades; Aude Fléchon; Christopher Pieczonka; Maria S Fernandes; Maarten Hulstijn; Andrew Lithio; Karim Nacerddine; Neeraj Agarwal
errShare
errSave
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer
errNEW ENGLAND JOURNAL OF MEDICINE
IF78.5
err2025-10-01
err1
PREAI
errShore, Neal D.; Luz, Murilo de Almeida; De Giorgi, Ugo; Gleave, Martin; Gotto, Geoffrey T.; Pieczonka, Christopher M.; Haas, Gabriel P.; Kim, Choung-Soo; Ramirez-Backhaus, Miguel; Rannikko, Antti; Kalac, Matko; Sridharan, Swetha; Rosales, Matt; Tang, Yiyun; Tutrone Jr, Ronald F.; Venugopal, Balaji; Villers, Arnauld; Woo, Henry H.; Wang, Fong; Freedland, Stephen J.
errShare
errSave
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients
errProstate Cancer and Prostatic Diseases
IF5.8
err2025-09-22
err0
errOAAI
errNeal D. Shore; Christopher M. Pieczonka; Sean Heron; Mukaram Gazi; David J. Cahn; Laurence H. Belkoff; Aaron D. Berger; Brian Mazzarella; Joseph Veys; David Morris; Richard Bevan-Thomas; Alexander Engelman; Paul Dato; David R. Wise; Mary Kay Hardwick; Kerry W. Aradhya; Brandie Heald; Robert L. Nussbaum; Kathryn E. Hatchell; Brianna Bucknor; Edward D. Esplin; Sarah M. Nielsen
errShare
errSave
Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer
errJOURNAL OF UROLOGY
IF6.8
err2024-12-01
err3
PREAI
errShore, Neal; Pieczonka, Christopher; Heron, Sean; Gazi, Mukaram; Cahn, David; Belkoff, Laurence H.; Berger, Aaron; Mazzarella, Brian; Veys, Joseph; Idom, Charles; Morris, David; Jayram, Gautam; Engelman, Alexander; Dato, Paul; Bevan-Thomas, Richard; Wise, David R.; Hardwick, Mary Kay; Rojahn, Susan; Layman, Paige; Heald, Brandie; Ellsworth, Rachel E.; Hatchell, Kathryn E.; Nussbaum, Robert L.; Nielsen, Sarah M.; Esplin, Edward D.
errShare
errSave
Prespecified interim analysis of the DARolutamide ObservationaL (DAROL) study in Black/African American patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)
errCANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
IF3.4
err2024-09-21
err0
PREAI
errYu, Evan Y.; Pieczonka, Christopher; Suzuki, Hiroyoshi; Briganti, Alberto; Luz, Murilo; Murphy, Declan; Adorjan, Patrick; Ghadessi, Mercedeh; Verholen, Frank; Armstrong, Andrew J.
errShare
errSave
Association of PD-L1 expression with clinical response to TAR-200 in the phase IIb SunRISe-1 trial
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errXylinas, E.; Pieczonka, C.; Jacob, J. M.; Necchi, A.; Daneshmand, S.; Simone, G.; Decaestecker, K.; Kulkarni, G.; Boegemann, M.; Guerrero-Ramos, F.; Callaway, J.; Beeharry, N.; Zhang, J.; Hampras, S.; Sweiti, H.; Stromberg, K.; Martin, J.; Shukla, A.; Raciti, P.; van der Heijden, M. S.
errShare
errSave
THIRD INTERIM ANALYSIS (IA3) OF THE DAROLUTAMIDE OBSERVATIONAL (DAROL) STUDY IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)
errJOURNAL OF UROLOGY
IF6.8
err2024-05-01
err0
PREAI
errGotto, Geoffrey; Suzuki, Hiroyoshi; Luz, Murilo; Briganti, Alberto; Yu, Evan Y.; Pieczonka, Christopher; Murphy, Declan; Malone, Ryan; Hamilton, Joelle; Chan, Jonathan E.; Sieber, Paul; Given, Robert W.; Adorjan, Patrick; Ghadessi, Mercedeh; Verholen, Frank; Armstrong, Andrew J.
errShare
errSave
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN
errBRITISH JOURNAL OF CANCER
IF6.8
err2023-11-11
err4
errOAAI
errShen, John; Chowdhury, Simon; Agarwal, Neeraj; Karsh, Lawrence I.; Oudard, Stephane; Gartrell, Benjamin A.; Feyerabend, Susan; Saad, Fred; Pieczonka, Christopher M.; Chi, Kim N.; Brookman-May, Sabine D.; Rooney, Brendan; Bhaumik, Amitabha; Mccarthy, Sharon A.; Bevans, Katherine B.; Mundle, Suneel D.; Small, Eric J.; Smith, Matthew R.; Graff, Julie N.
errShare
errSave
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
errNEW ENGLAND JOURNAL OF MEDICINE
IF78.5
err2023-10-19
err84
PREAI
errFreedland, Stephen J.; Luz, Murilo de Almeida; De Giorgi, Ugo; Gleave, Martin; Gotto, Geoffrey T.; Pieczonka, Christopher M.; Haas, Gabriel P.; Kim, Choung-Soo; Ramirez-Backhaus, Miguel; Rannikko, Antti; Tarazi, Jamal; Sridharan, Swetha; Sugg, Jennifer; Tang, Yiyun; Tutrone, Ronald F.; Venugopal, Balaji; Villers, Arnauld; Woo, Henry H.; Zohren, Fabian; Shore, Neal D.
errShare
errSave
Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK
errANNALS OF ONCOLOGY
IF65.4
err2023-10-01
err2
errOAAI
errFreedland, S. J.; Gleave, M. E.; De Giorgi, U. F. F.; Rannikko, A.; Pieczonka, C.; Sridharan, S.; Brasso, K.; Woo, H.; Caamano, A. Gomez; Saranchuk, J.; Nordquist, L. T.; Ferreira, U.; Tang, Y.; Rosbrook, B.; Haas, G. P.; Rosales, M.; Zohren, F.; Shore, N. D.
errShare
errSave
A phase I/II efficacy and safety study of LAE001/prednisone and afuresertib in patients with metastatic castrationresistant prostate cancer (mCRPC) following 1-3 lines of standard of care
errANNALS OF ONCOLOGY
IF65.4
err2023-10-01
err0
errOAAI
errDiamond, E.; Kwak, C.; Orr, D.; Bamidele, A.; Jeong, I. G.; Bessudo, A.; Dunshee, C.; Henderson, S.; Joung, J. Y.; Lee, S.; Chaves, J.; Slater, D.; Patnaik, A.; Pieczonka, C.; Lee, W.; Choi, Y. D.; Guo, P.; Ma, K.; Cao, E.; Yue, Y.
errShare
errSave
Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial
errEUROPEAN UROLOGY ONCOLOGY
IF9.3
err2023-10-01
err8
errOAAI
errShore, Neal; Gazi, Mukaram; Pieczonka, Christopher; Heron, Sean; Modh, Rishi; Cahn, David; Belkoff, Laurence H.; Berger, Aaron; Mazzarella, Brian; Veys, Joseph; Idom, Charles; Morris, David; Jayram, Gautam; Engelman, Alexander; Bukkapatnam, Raviender; Dato, Paul; Bevan-Thomas, Richard; Cornell, Robert; Wise, David R.; Hardwick, Mary Kay; Hernandez, Ryan D.; Rojahn, Susan; Layman, Paige; Hatchell, Kathryn E.; Heald, Brandie; Nussbaum, Robert L.; Nielsen, Sarah M.; Esplin, Edward D.
errShare
errSave
Health-related quality of life (HRQoL) in nonmetastatic hormone-sensitive prostate cancer (nmHSPC) patients (pts) with high-risk biochemical recurrence (BCR) from the EMBARK study
errANNALS OF ONCOLOGY
IF65.4
err2023-10-01
err2
errOAAI
errFreedland, S. J.; Gleave, M. E.; De Giorgi, U. F. F.; Rannikko, A.; Pieczonka, C.; Tutrone, R.; Venugopal, B.; Woo, H.; Backhaus, M. Ramirez; Supiot, S.; Lantz, A.; Ganguli, A.; Ivanova, J.; Kral, P.; Huang, S-P.; Saad, F.; Shore, N. D.
errShare
errSave
Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial
errBJU INTERNATIONAL
IF4.4
err2022-09-29
err3
PREAI
errShore, Neal D.; Stenzl, Arnulf; Pieczonka, Christopher; Klaassen, Zachary; Aronson, William J.; Karsh, Lawrence; Ryan, Charles J.; Ortiz, Jorge; Srinivasan, Shankar; Mohamed, Ateesha F.; Verholen, Frank
errShare
errSave
Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN
errANNALS OF ONCOLOGY
IF65.4
err2021-09-01
err2
errOAAI
errShen, J.; Chowdhury, S.; Agarwal, N.; Karsh, L. I.; Oudard, S.; Gartrell, B. A.; Feyerabend, S.; Saad, F.; Pieczonka, C. M.; Chi, K. N.; Brookman-May, S. D.; Rooney, B.; Bhaumik, A.; Londhe, A.; McCarthy, S. A.; Bevans, K. B.; Mundle, S. D.; Small, E. J.; Smith, M. R.; Graff, J. N.
errShare
errSave
Universal germline testing of prostate cancer patients: Are genetic testing guidelines an aid or an impediment to precision therapy?
errANNALS OF ONCOLOGY
IF65.4
err2021-09-01
err0
errOAAI
errHardwick, M. K.; Esplin, E.; Mazzerelli, B.; Morris, D.; Heron, S.; Veys, J.; Engelman, A.; Dato, P.; Bevan-Thomas, R.; Wise, D.; Cornell, R.; Berger, A.; Nielsen, S.; Hatchell, K.; Nussbaum, R.; Gazi, M.; Pieczonka, C. M.; Belkoff, L.; Cahn, D. J.; Shore, N. D.
errShare
errSave
A phase I dose-escalation study of LAE001/prednisone plus afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment
errANNALS OF ONCOLOGY
IF65.4
err2021-09-01
err0
errOAAI
errBessudo, A.; Wang, X.; Strauss, J. F.; Slater, D. E.; Pieczonka, C.; Guo, P.; Liu, J.; Yue, Y.; Lu, C.
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
S
Shahrokh F. Shariat
H-index: 146 · Papers: 2.9K
P
Philip W. Kantoff
H-index: 137 · Papers: 1.4K
C
Charles G. Drake
H-index: 133 · Papers: 1.2K
F
Fred Saad
H-index: 127 · Papers: 1.9K
M
Martin Gleave
H-index: 126 · Papers: 1.8K
View more